Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26157285 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Margherita Ratti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Oncology and Hematology Department, Piacenza General Hospital, Via Taverna 49, 29121 Piacenza, PC, Italy. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gastric cancer (GC) remains a major cause of cancer-related mortality worldwide, with human epidermal growth factor receptor 2 (HER2)-positive disease representing a clinically relevant subset. Trastuzumab combined with chemotherapy is the standard first-line treatment in advanced settings, following the landmark ToGA trial. However, resistance to trastuzumab has emerged as a significant limitation, prompting the need for more effective second-line therapies. Trastuzumab deruxtecan, a novel antibody–drug conjugate (ADC) composed of trastuzumab linked to a cytotoxic payload, has demonstrated promising efficacy in trastuzumab-refractory, HER2-positive GC, including cases with heterogeneous HER2 expression. Other HER2-targeted ADCs are also under investigation as potential alternatives. In addition, strategies to overcome resistance include HER2-specific immune-based therapies, such as peptide vaccines and chimeric antigen receptor T cell therapies, as well as antibodies targeting distinct HER2 domains or downstream signaling pathways like PI3K/AKT. These emerging approaches aim to improve efficacy in both HER2-high and HER2-low GC. As HER2-targeted treatments evolve, addressing resistance mechanisms and optimizing therapy for broader patient populations is critical. This review discusses current and emerging HER2-directed strategies in GC, focusing on trastuzumab deruxtecan and beyond, and outlines future directions to improve outcomes for patients with HER2-positive GC across all clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology and Hematology Department, Piacenza General Hospital, Via Taverna 49, 29121 Piacenza, PC, Italy.
- Pharmacy Unit, Piacenza General Hospital, Via Taverna 49, 29121 Piacenza, PC, Italy.
- School of Medical Oncology, University Hospital of Modena and Reggio Emilia, Largo del Pozzo 71, 41124 Modena, MO, Italy.
- Division of Medical Oncology, University Hospital of Modena, 41124 Modena, MO, Italy.
- Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, MI, Italy.
ORCID-Profile: Chiara Citterio, Elena Orlandi, Stefano Vecchia, Ilaria Toscani, Michele Ghidini
Zitieren
APA
Ratti, M., Citterio, C., Orlandi, E., Vecchia, S., Anselmi, E., Toscani, I., Rotolo, M., Salati, M., & Ghidini, M. (2025). Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157285
Vancouver
Ratti M, Citterio C, Orlandi E, Vecchia S, Anselmi E, Toscani I, et al. Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157285
BibTeX
@article{Ratti2025,
author = {Ratti, Margherita and Citterio, Chiara and Orlandi, Elena and Vecchia, Stefano and Anselmi, Elisa and Toscani, Ilaria and Rotolo, Martina and Salati, Massimiliano and Ghidini, Michele},
title = {Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26157285}
}
EUVIMED